Monopotassium salt of an I B kinase inhibitor

The present invention is directed to the compound of formula II, or a solvate thereof. The invention is also directed to the pharmaceutical use of the compound as an I B kinase inhibitor, crystalline anhydrous and hydrated forms of the compound, pharmaceutical compositions comprising the compounds of the invention, and stable pharmaceutical products comprising the compound. As an inhibitor of I B kinase, the compound of the invention, functions via the selective inhibition of IKK, particularly an IKK-2 inhibitor; as well as exhibiting localized activity, as opposed to a systemic activity. Such an inhibitor is particularly useful for treating a patient suffering from or subject to IKK-2 mediated pathological diseases or conditions, e.g., asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), or COPD exacerbations, that could be ameliorated by the targeted administering of the inhibitor.